Huntington’s Disease: Therapeutics

Huntington’s disease is a hereditary neurodegenerative disease characterized by poor coordination and involuntary body movements. Here is the latest research on Huntington’s disease therapeutics.

January 21, 2022

SUPT4H1-edited stem cell therapy rescues neuronal dysfunction in a mouse model for Huntington's disease.

Npj Regenerative Medicine
Hyun Jung ParkJihwan Song
January 21, 2022
Open Access

Monitoring Neuronal Network Disturbances of Brain Diseases: A Preclinical MRI Approach in the Rodent Brain.

Frontiers in Cellular Neuroscience
Annemie Van der Linden, Mathias Hoehn
January 21, 2022

Gene Therapy for Huntington's Disease: The Future Is in Gene Editing.

Human Gene Therapy
Ana Rita Batista
January 21, 2022

Passive immunization against phosphorylated tau improves features of Huntington's disease pathology.

Molecular Therapy : the Journal of the American Society of Gene Therapy
Melanie AlpaughFrancesca Cicchetti
January 21, 2022

A video-based discussion of movement disorders in paediatric anti NMDAR encephalitis: A case series from Eastern India.

European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society
Amlan Kusum DattaAlak Pandit
January 15, 2022

Recent advances in preventing neurodegenerative diseases.

Faculty Reviews
Shih-Ching ChouTae-In Kam
January 13, 2022

Deep brain stimulation for chorea-acanthocytosis: a systematic review.

Neurosurgical Review
Yang WuWei Wang
January 12, 2022

Possibilities and challenges of small molecule organic compounds for the treatment of repeat diseases.

Proceedings of the Japan Academy. Series B, Physical and Biological Sciences
Kazuhiko Nakatani
January 10, 2022

Timing of selective basal ganglia white matter loss in premanifest Huntington's disease.

NeuroImage. Clinical
Paul ZeunTrackOn-HD and HD-YAS Investigators
January 10, 2022

The key players of parthanatos: opportunities for targeting multiple levels in the therapy of parthanatos-based pathogenesis.

Cellular and Molecular Life Sciences : CMLS
Libo LiuRuoxi Wang
January 11, 2022
Open Access

Targeted Genetic Reduction of Mutant Huntingtin Lessens Cardiac Pathology in the BACHD Mouse Model of Huntington's Disease.

Frontiers in Cardiovascular Medicine
Saemi ParkChristopher S Colwell
January 11, 2022

The Efficacy and Safety of Pridopidine on Treatment of Patients with Huntington's Disease: A Systematic Review and Meta-Analysis.

Movement Disorders Clinical Practice
Moamen Mostafa AslaWalaa A Kamel
January 11, 2022

Time-to-event prediction using survival analysis methods for Alzheimer's disease progression.

Alzheimer's & Dementia : Translational Research & Clinical Interventions
Rahul SharmaRobin G Qiu
January 11, 2022

Neuroprotective potential of Celastrus paniculatus seeds against common neurological ailments: a narrative review.

Journal of Complementary & Integrative Medicine
Divya SankaramourthySudha Rani Sadras
January 11, 2022

Pharmacological Management of Apathy in Dementia.

CNS Drugs
Laiba AzharNathan Herrmann
January 9, 2022
Open Access

Analysis of psychiatric consultations in the department of neurology and stroke unit: diagnosis and therapy.

Psychiatria polska
Tomasz ChmielaAgnieszka Gorzkowska
January 8, 2022
Open Access

Anti-inflammatory role of GM1 and other gangliosides on microglia.

Journal of Neuroinflammation
Danny GalleguillosSimonetta Sipione

Sign up to follow this feed and discover related papers.

Related Feeds

3D Cellular Models of Brain and Neurodegeneration

Brain organoids are three-dimensional in vitro cellular models of the brain that can recapitulate many processes such as the neurodevelopment. In addition, these organoids can be combined with other cell types, such as neurons and astrocytes to study their interactions in assembloids. Disease processes can also be modeled by induced pluripotent stem cell-derived organoids and assembloids from patients with neurodegenerative disorders. Discover the latest research on the models here.


TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here is the latest research on ALS and prions.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research in this field.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

Age-related Dementia

Dementias are a group of conditions, including Alzheimer's disease, vascular dementia, and frontotemporal dementia, characterized by deficiencies in cognitive abilities. Age-related dementia refers to dementias that occur in older individuals, usually 60+ years old, in contrast to early-onset dementia. Follow the latest research on age-related dementia here.

Alexander Disease

Alexander disease is a rare leukodystrophy caused by mutations in the astrocyte-specific intermediate filament protein glial fibrillary acidic protein (GFAP). Here is the latest research on this disease.

© 2022 Meta ULC. All rights reserved